Hepatobiliary Malignancies
Conditions
Interventions
Case series (Part 1):N/A
Case series (Part 2):N/A
Sponsors
Zhongshan Hospital Affiliated to Fudan University; Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Part 1: 1. Age: Male or female patients aged 18 and above 2. Primary liver cancer 3. Using immunotherapy, including a. Initial treatment stage, patients within 3 weeks of the first medication use b. In the treatment stage, patients who are receiving treatment and taking medication for 3-6 months 4. Voluntary signing of informed consent form Part 2: 1. Age: Male or female patients aged 18 and above 2. Primary liver cancer 3. Initial treatment: Receive the first dose of PD-1/PD-L1 immunotherapy for no more than 3 weeks 4. Voluntary signing of informed consent form
Exclusion criteria
Exclusion criteria: 1. Currently participating in clinical trials of other PD-1/PD-L1 drugs 2. Judged by doctors to have poor understanding or compliance, and not suitable for participating in this survey
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse reaction assessment scale;Quality of Life Assessment Scale (EORTC QLQ-C30); | — |
Secondary
| Measure | Time frame |
|---|---|
| Chinese Patient Immunotherapy Specific Questionnaire; | — |
Countries
China
Contacts
Public ContactXu Li; Sun Huichuan
Sun Yat-sen University Cancer Center; Zhongshan Hospital Affiliated to Fudan University
Outcome results
None listed